The presence of Helicobacter pylori in the liver depends on the Th1, Th17 and Treg cytokine profile of the patient.

The hypothesis that Helicobactermight be a risk factor for human liver diseases has arisen after the detection of Helicobacter DNA in hepatic tissue of patients with hepatobiliary diseases. Nevertheless, no explanation that justifies the presence of the bacterium in the human liver has been proposed. We evaluated the presence of Helicobacterin the liver of patients with hepatic diseases of different aetiologies.

Immune response and gene polymorphism profiles in Crohn's disease and ulcerative colitis.

Background: Polymorphisms in genes linked to the innate and adaptive immune response may be involved in inflammatory bowel disease pathogenesis. Our aim was to investigate associations among IL1B-511, IL1B-31, IL1RN, TNFA-307, TLR-2, TLR-4, IL2-330, NOD2 G908R, NOD2 L1007fsinsC polymorphisms and both Crohn's disease (CD) and ulcerative colitis (UC) in a Brazilian population.

Methods: We studied 43 patients with CD, 42 with UC, and 541 blood donors.

Isolation of Helicobacter pylori from the intestinal mucosa of patients with Crohn's disease.

Background: Helicobacter species are associated with inflammatory bowel disease in rodents and in nonhuman primates. Therefore, we prospectively investigated the presence of Helicobacter species in the intestinal mucosa of patients with and without Crohn's disease by culture and polymerase chain reaction (PCR) assays.

Materials And Methods: Mucosal fragments were obtained from the ileum, different colon regions, and rectum of 43 patients with Crohn's disease and of 74 patients without inflammatory bowel disease.

Helicobacter species in the intestinal mucosa of patients with ulcerative colitis.

In a search for Helicobacter species in the intestinal mucosae of 42 patients with ulcerative colitis (UC) and 74 without UC, only H. pylori was found. Although the bacterium was detected in UC patients by culture (7.

Factors associated with treatment failure of Helicobacter pylori infection in a developing country.

Background: Although no regimen can eradicate in 100% of patients, factors that may affect the eradication rates have been poorly studied.

Goal: To evaluate factors associated with treatment failure.

Study: One hundred patients were treated with pantoprazole plus clarithromycin and furazolidone for eradication.